TY - JOUR
T1 - Assessment of the performance of the SarQoL® questionnaire in screening for sarcopenia in older people
AU - Geerinck, Anton
AU - Dawson-Hughes, Bess
AU - Beaudart, Charlotte
AU - Locquet, Médéa
AU - Reginster, Jean Yves
AU - Bruyère, Olivier
N1 - Funding Information:
AG is supported by a FRIA doctoral grant from the Fonds de la Recherche Scientifique (F.R.S-FNRS).
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
PY - 2021/8
Y1 - 2021/8
N2 - Background: Because of its low prevalence and the need for physical tests to establish a diagnosis, recruiting sarcopenic people for clinical studies can be a resource-intensive process. Aims: We investigated whether the SarQoL®, a 55-item questionnaire designed to measure quality of life in sarcopenia, could be used to identify older people with a high likelihood of being sarcopenic, and to compare its performance to the SARC-F tool. Methods: We performed a secondary analysis of data from older, community-dwelling participants of the SarcoPhAge study, evaluated for sarcopenia according to the EWGSOP2 criteria, and who completed the SarQoL® and SARC-F questionnaires. We determined the optimal threshold to distinguish between sarcopenic and non-sarcopenic people with the Youden index. Screening performance was evaluated with the area under the curve (AUC) and by calculating sensitivity and specificity. Results: The analysis of 309 participants provided an optimal threshold value of ≤ 52.4 points for identifying people with sarcopenia with the SarQoL® questionnaire, which resulted in a sensitivity of 64.7% (41.1–84.2%), a specificity of 80.5% (75.7–84.7%) and an AUC of 0.771 (0.652–0.889). Compared to the SARC-F, the SarQoL® has greater sensitivity (64.7% vs 52.39%), but slightly lower specificity (80.5% vs. 86.6%). Discussion: The SarQoL® questionnaire showed acceptable screening accuracy, on par with the SARC-F. The optimal threshold of ≤ 52.4 points should be confirmed in other cohorts of older people. Conclusions: This exploratory study showed that the SarQoL® could potentially be applied in a screening strategy, with the added benefit of providing a measure of QoL at the same time.
AB - Background: Because of its low prevalence and the need for physical tests to establish a diagnosis, recruiting sarcopenic people for clinical studies can be a resource-intensive process. Aims: We investigated whether the SarQoL®, a 55-item questionnaire designed to measure quality of life in sarcopenia, could be used to identify older people with a high likelihood of being sarcopenic, and to compare its performance to the SARC-F tool. Methods: We performed a secondary analysis of data from older, community-dwelling participants of the SarcoPhAge study, evaluated for sarcopenia according to the EWGSOP2 criteria, and who completed the SarQoL® and SARC-F questionnaires. We determined the optimal threshold to distinguish between sarcopenic and non-sarcopenic people with the Youden index. Screening performance was evaluated with the area under the curve (AUC) and by calculating sensitivity and specificity. Results: The analysis of 309 participants provided an optimal threshold value of ≤ 52.4 points for identifying people with sarcopenia with the SarQoL® questionnaire, which resulted in a sensitivity of 64.7% (41.1–84.2%), a specificity of 80.5% (75.7–84.7%) and an AUC of 0.771 (0.652–0.889). Compared to the SARC-F, the SarQoL® has greater sensitivity (64.7% vs 52.39%), but slightly lower specificity (80.5% vs. 86.6%). Discussion: The SarQoL® questionnaire showed acceptable screening accuracy, on par with the SARC-F. The optimal threshold of ≤ 52.4 points should be confirmed in other cohorts of older people. Conclusions: This exploratory study showed that the SarQoL® could potentially be applied in a screening strategy, with the added benefit of providing a measure of QoL at the same time.
KW - Sarcopenia
KW - SarQoL
KW - Screening
KW - Sensitivity
KW - Specificity
UR - http://www.scopus.com/inward/record.url?scp=85110851838&partnerID=8YFLogxK
U2 - 10.1007/s40520-021-01913-z
DO - 10.1007/s40520-021-01913-z
M3 - Article
C2 - 34212342
AN - SCOPUS:85110851838
SN - 1594-0667
VL - 33
SP - 2149
EP - 2155
JO - Aging Clinical and Experimental Research
JF - Aging Clinical and Experimental Research
IS - 8
ER -